[{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"8","companyTruncated":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"8","companyTruncated":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sunobinop","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMB-150","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"PureTech Health","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"IMB-150","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"Imbrium Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Imbrium Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Imbrium Therapeutics \/ Imbrium Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Imbrium Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of overactive bladder syndrome.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 11, 2025

                          Lead Product(s) : Sunobinop

                          Therapeutic Area : Urology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of overactive bladder syndrome.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 07, 2025

                          Lead Product(s) : Sunobinop

                          Therapeutic Area : Urology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 09, 2024

                          Lead Product(s) : Sunobinop

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Purdue Pharmaceuticals L.P

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 09, 2024

                          Lead Product(s) : Sunobinop

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Purdue Pharmaceuticals L.P

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of moderate to severe alcohol use disorder.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 08, 2024

                          Lead Product(s) : Sunobinop

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 29, 2024

                          Lead Product(s) : Sunobinop

                          Therapeutic Area : Urology

                          Highest Development Status : Phase I

                          Sponsor : Purdue Pharmaceuticals L.P

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 06, 2023

                          Lead Product(s) : Sunobinop

                          Therapeutic Area : Urology

                          Highest Development Status : Phase I

                          Sponsor : Purdue Pharmaceuticals L.P

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 20, 2022

                          Lead Product(s) : IMB-150

                          Therapeutic Area : Urology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Under the terms of the agreement, Imbrium is responsible for all future development activities and funding for LYT-503/IMB-150, for which an IND filing is planned for early 2022.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 08, 2021

                          Lead Product(s) : IMB-150

                          Therapeutic Area : Urology

                          Highest Development Status : Preclinical

                          Recipient : PureTech Health

                          Deal Size : $59.5 million

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor i...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 28, 2020

                          Lead Product(s) : Sunobinop

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank